
30
Apr, 2020
Invasive ventilation in children during COVID-19 pandemic
30 April 2020
A webinar by ESPNIC
30
Apr, 2020
30 April 2020
A webinar by ESPNIC
29
Apr, 2020
Pediatr Infect Dis J, April 2020
28
Apr, 2020
28 April 2020
A webinar by ESPNIC
28
Apr, 2020
J Clin Virol, April 2020
28
Apr, 2020
28
Apr, 2020
28
Apr, 2020
Authors: Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, Ellis S, Sharland M. Published in: Bulletin of the World Health Organization, April 2020 Objective To compare dosing guidance in the paediatric formularies of high-income countries and emerging economies for 32 commonly prescribed antibiotics on the World Health Organization’s (WHO’s) 2017 Model List of Essential Medicines for Children. Methods We identified paediatric antibiotic guidelines that were either widely used internationally or originated in countries in which antibiotic use has increased markedly in recent years (i.e. Brazil, China, […]
27
Apr, 2020
27 April 2020
An overview of COVID-19 pandemic from a wildlife biology perspective
26
Apr, 2020
Authors: L. Hill, E. Jacqz-Aigrain, V. Elie, W. Zhao, M. Clements, M. Turner, I. Lutsar, P. Heath, E. Roilides, S. Walker, M. Sharland Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020 Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sepsis (LOS), however, a consensus on optimal vancomycin dosing and duration is lacking. Robust neonatal clinical pharmacokinetic (PK) data comparing different vancomycin dosing regimens remain sparse. NeoVanc (NCT02790996) is a European, randomised controlled, non-inferiority trial comparing an optimised […]
26
Apr, 2020
Authors: L. Hill, M. Clements, M. Turner, I. Lutsar, E. Jacqz-Aigrain, P. Heath, E. Roilides, S. Walker, M. Sharland Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020 Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sep- sis (LOS). Robust neonatal clinical outcome data comparing different vancomycin dosing regimens is lacking. NeoVanc (NCT02790996) is a European, multicentre, phase IIb, randomised controlled, non-inferiority trial comparing an optimised and standard vancomycin regimen in infants aged ≤90 days with known/suspected Gram-positive […]